$QCOM

Arete Adjusts Price Target on QUALCOMM to $305 From $314

Arete Research lowered its price target for QUALCOMM from $314 to $305. The stock was trading at $178.40, up 3.35% in pre-market. QUALCOMM recently won $2 in damages in a licensing lawsuit against Arm Tech.

Original reporting
Published Oct 16, 2026, 9:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 9:55 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$QCOM
Bearish
high confidence
Mentioned
$QCOM
Relevance
6/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$QCOMBearishMed
01

Why it matters

The downgrade signals a shift in analyst expectations, which can trigger short‑term price adjustments.

02

Market read

Analyst target cuts are a common catalyst for short‑term price moves, especially in high‑visibility tech stocks.

03

What to watch

Potential upside from upcoming 5G rollouts or contract wins not reflected in the target change.

Relevance 6/10Novelty 6/10Timing: pre‑market today

Background

Arete's composite rating methodology combines valuation, EPS revisions, and visibility metrics to generate price‑target recommendations.

Company-level read

Ticker impact

$QCOMBearishHigh confidence
Context

Arete lowered Qualcomm's price target to $305 from $314, indicating a fresh analyst downgrade.

Expected impact

downward pressure as the market prices in the lower target

Evidence & confidence

Analyst price‑target cuts are immediate signals that the consensus view has weakened, prompting short‑term sell interest.

Market effects

May weigh on other semiconductor peers as analysts reassess valuation multiples.

Limited to US tech equities; no broader regional effect.

Minor, confined to investors tracking Qualcomm and related chip stocks.

Counterpoint

Some investors may view the cut as an overreaction and see buying opportunity if fundamentals remain strong.

Key entities

  • Qualcomm

    US‑listed semiconductor and telecommunications equipment maker.

  • Arete

    Research provider issuing the price‑target adjustment.

Related articles

$QCOMMed

Qualcomm Faces Heating Setback in Galaxy S27

Qualcomm's next-gen chip, Snapdragon 8 Elite Extreme 6th Gen, faces heating issues, potentially delaying its use in Samsung's Galaxy S27 Ultra. Samsung may switch to its in-house Exynos 2700 chip, developed using a 2-nanometer process, which could impact Qualcomm's revenue and Samsung's semiconductor strategy. Industry experts suggest Qualcomm may struggle to resolve the heating issue quickly.

$QCOMMed

Qualcomm Vs. Arm: The Jury Verdict Is In. Who Came Out On Top?

A jury found Arm breached its agreement with Qualcomm and interfered with its Meta relationship, but rejected several other claims. Qualcomm was awarded $2 in damages, but key decisions on licensing and remedies remain with the judge. The outcome could impact future licensing talks and business practices. Arm also claimed victory, as it avoided substantial financial damages and defeated several claims.

$QCOMMed

Jury finds Arm guilty in licensing breach, Qualcomm awarded just $2 in total

A Delaware jury found Arm guilty of breaching a licensing agreement with Qualcomm and interfering with its business relations, awarding Qualcomm $2 in damages. Arm disputes the ruling, claiming it acted in good faith. Qualcomm seeks to stop paying royalties to Arm for five years, a decision pending with Judge Maryellen Noreika. The dispute began after Qualcomm's 2021 acquisition of Nuvia, with Qualcomm alleging Arm withheld chip-testing tools and leaked threats to end a key license.

$ARMLow

Arm-Qualcomm legal fight ends in limited verdict, larger stakes remain

A Delaware jury found Arm breached its licensing agreement with Qualcomm, awarding $2 in damages. Qualcomm seeks to stop paying royalties, while Arm argues the provision is unenforceable. The dispute follows earlier legal battles over Nuvia's acquisition. Both companies are expanding into new markets. Analysts note the ruling reduces uncertainty but Qualcomm's PC market challenges remain.

$QCOMMed

Arm breached Qualcomm license agreement, jury finds

A jury found Arm breached its license agreement with Qualcomm, awarding Qualcomm $2. Qualcomm accused Arm of failing to provide software tools and interfering with a chip deal. Arm maintained it acted in good faith. The verdict is part of an ongoing legal dispute between the two companies.

$QCOMMed

Qualcomm at $175: The Narrative Shift Sending Capital Out The Door

Qualcomm (QCOM) reported fiscal Q3 with handset revenue down 20% YoY to $5.09B and automotive revenue up 61% to $1.59B. Non-GAAP EPS was $2.21, slightly missing estimates. Management raised its fiscal 2029 non-handset revenue target to $40B. The stock trades at a forward P/E of 20, with a PEG ratio of 0.88 and a free cash flow yield of 6.79%. Analysts have a $194 average target, with most rating it a Hold.